Annexon, Inc. announced the appointment of  William ?BJ? Jones to its board of directors. Mr. Jones brings 30 years of U.S. and global commercial and launch experience in the biotechnology industry.

Mr. Jones joins Annexon with demonstrated commercial success at both large pharmaceutical and small biotechnology companies, with particular experience in driving mass-market product launch strategies for brands. He currently serves as chief commercial officer of NewAmsterdam Pharma Company N.V. where he leads all commercial functions, including marketing, market access, sales, medical science engagement and commercial operations. Previously Mr. Jones was the chief commercial officer, migraine & common diseases at Biohaven Pharmaceuticals, which was acquired by Pfizer for $11.6 billion.

Mr. Jones has held executive leadership roles of increasing responsibility at Takeda Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim and NitroMed, and has significant experience in large market product launches, including Nurtec® ODT, Abilify®, Farxiga®, Pradaxa®, BiDil® and Excedrin Migraine®. He currently serves on the board of Apogee Therapeutics. Mr. Jones is a graduate of the United States Air Force Academy and attained the rank of Major through his active duty and reserve service.

He holds an M.B. A from Stanford Graduate School of Business and an M.S. in Industrial Engineering from Texas A&M University.